The erythropoietin receptor and its expression in tumor cells and other tissues

Oncologist

Volumn 9, Issue SUPPL. 5, 2004, Pages 18-30

  Farrell, Francis ^a   Lee, Adrian ^b  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Anemia; Angiogenesis; CNS; EPO R activation; EPO R structure; Epoetin alfa; Tumors

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ERYTHROPOIETIN RECEPTOR; RECOMBINANT ERYTHROPOIETIN; VASCULOTROPIN;

AMNESIA; ANEMIA; ANGIOGENESIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER TISSUE; COGNITIVE DEFECT; CONFERENCE PAPER; ENCEPHALITIS; EPILEPSY; HUMAN; LANGUAGE DISABILITY; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; QUALITY OF LIFE; SIDE EFFECT; SIGNAL TRANSDUCTION; STROKE; TREATMENT OUTCOME; TUMOR CELL;

CELL HYPOXIA; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, ERYTHROPOIETIN; SIGNAL TRANSDUCTION;

EID: 10644267714     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-90005-18     Document Type: Conference Paper

References (72)

1. Lacombe C, Mayeux P. The molecular biology of erythropoietin. Nephrol Dial Transplant 1999;14(suppl 2):22-28.
2. Lappin T. The cellular biology of erythropoietin receptors. The Oncologist 2003;8(suppl 1):15-18.
3. Lappin TR, Maxwell AP, Johnston PG. EPO's alter ego: erythropoietin has multiple actions. STEM CELLS 2002;20:485-492.
4. Sasaki R, Masuda S, Nagao M. Erythropoietin: multiple physiological functions and regulation of biosynthesis. Biosci Biotechnol Biochem 2000;64:1775-1793.
5. Mulcahy L. The erythropoietin receptor. Semin Oncol 2001;28(suppl 8):19-23.
6. Dordal MS, Wang FF, Goldwasser E. The role of carbohydrate in erythropoietin action. Endocrinology 1985;116:2293-2299.
7. Leyland-Jones B. Trastuzumab: hopes and realities. Lancet Oncol 2002;3:137-144.
8. Barbone FP, Johnson DL, Farrell FX et al. New epoetin molecules and novel therapeutic approaches. Nephrol Dial Transplant 1999;14(suppl 2):80-84.
9. Connolly PJ, Wetter SK, Murray WV et al. Synthesis and erythropoietin receptor binding affinities of N,N-disubstituted amino acids. Bioorg Med Chem Lett 2000;10:1995-1999.
10. Livnah O, Stura EA, Johnson DL et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 1996;273:464-471.
11. Syed RS, Reid SW, Li C et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 1998;395:511-516.
12. Lacombe C, Mayeux P. Biology of erythropoietin. Haematologica 1998;83:724-732.
13. Klingmuller U, Wu H, Hsiao JG et al. Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors. Proc Natl Acad Sci USA 1997;94:3016-3021.
14. de la Chapelle A, Träskelin AL, Juvonen E. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Natl Acad Sci USA 1993;90:4495-4499.
15. Mui AL, Wakao H, Kinoshita T et al. Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation. EMBO J 1996;15:2425-2433.
16. Verdier F, Chretien S, Muller O et al. Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STATS) activation. Possible involvement of the ubiquitinated Cis protein. J Biol Chem 1998;273:28185-28190.
17. Wojchowski DM, Gregory RC, Miller CP et al. Signal transduction in the erythropoietin receptor system. Exp Cell Res 1999;253:143-156.
18. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001;16(suppl 3):3-13.
19. Bernaudin M, Marti HH, Roussel S et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 1999;19:643-651.
20. Brines ML, Ghezzi P, Keenan S et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10526-10531.
21. Morishita E, Masuda S, Nagao M et al. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997;76:105-116.
22. Sakanaka M, Wen TC, Matsuda S et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998;95:4635-4640.
23. Acs G, Acs P, Beckwith SM et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561-3565.
24. Acs G, Zhang PJ, Rebbeck TR et al. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 2002;95:969-981.
25. Arcasoy MO, Amin K, Karayal AF et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 2002;82:911-918.
26. Yasuda Y, Fujita Y, Masuda S et al. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 2002;23:1797-1805.
27. Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 2000;58:647-657.
28. Goonewardene TI, Sowter HM, Harris AL. Hypoxia-induced pathways in breast cancer. Microsc Res Tech 2002;59:41-48.
29. Ten VS, Pinsky DJ. Endothelial response to hypoxia: physiologic adaptation and pathologic dysfunction. Curr Opin Crit Care 2002;8:242-250.
30. Anagnostou A, Lee ES, Kessimian N et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990;87:5978-5982.
31. Anagnostou A, Liu Z, Steiner M et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994;91:3974-3978.
32. Masuda S, Nagao M, Takahata K et al. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 1993;268:11208-11216.
33. Mioni R, Gottardello F, Bordon P et al. Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells. Acta Endocrinol (Copenh) 1992;127:459-465.
34. Ogilvie M, Yu X, Nicolas-Metral V et al. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem 2000;275:39754-39761.
35. Fraser JK, Tan AS, Lin FK et al. Expression of specific high-affinity binding sites for erythropoietin on rat and mouse megakaryocytes. Exp Hematol 1989;17:10-16.
36. Selzer E, Wacheck V, Kodym R et al. Erythropoietin receptor expression in human melanoma cells. Melanoma Res 2000;10:421-426.
37. Rosti V, Pedrazzoli P, Ponchio L et al. Effect of recombinant human erythropoietin on hematopoietic and non-hematopoietic malignant cell growth in vitro. Haematologica 1993;78:208-212.
38. Westphal G, Niederberger E, Blum C et al. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori 2002;88:150-159.
39. Thews O, Kelleher DK, Vaupel P. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 2001;61:1358-1361.
40. Mittelman M, Neumann D, Peled A et al. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 2001;98:5181-5186.
41. Blackwell K, Gascón P, Sigounas G et al. rHuEPO and improved treatment outcomes: potential modes of action. The Oncologist 2004;9(suppl 5):41-47.
42. Stüben G, Thews O, Pottgen C et al. Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol 2001;127:346-350.
43. Stüben G, Thews O, Pöttgen C et al. Impact of anemia prevention by recombinant human erythropoietin on the sensitivity of xenografted glioblastomas to fractionated irradiation. Strahlenther Onkol 2003;179:620-625.
44. Kelleher DK, Mattheinsen U, Thews O et al. Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res 1996;56:4728-4734.
45. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
46. Ribatti D, Presta M, Vacca A et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999;93:2627-2636.
47. Carlini RG, Dusso AS, Obialo CI et al. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int 1993;43:1010-1014.
48. Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 1995;47:740-745.
49. Vogel V, Kramer HJ, Backer A et al. Effects of erythropoietin on endothelin-1 synthesis and the cellular calcium messenger system in vascular endothelial cells. Am J Hypertens 1997;10:289-296.
50. Maxwell PH, Dachs GU, Gleadle JM et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997;94:8104-8109.
51. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-674.
52. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 2000;35:71-103.
53. Tan CC, Eckardt KU, Firth JD et al. Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia. Am J Physiol 1992;263:F474-F481.
54. Marti HH, Bernaudin M, Petit E et al. Neuroprotection and angiogenesis: dual role of erythropoietin in brain ischemia. News Physiol Sci 2000;15:225-229.
55. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992;12:5447-5454.
56. Vaupel P. The role of hypoxia-induced factors in tumor progression. The Oncologist 2004;9(suppl 5):10-17.
57. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. The Oncologist 2004;9(suppl 5):4-9.
58. Digicaylioglu M, Bichet S, Marti HH et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA 1995;92:3717-3720.
59. Dame C, Juul SE, Christensen RD. The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential. Biol Neonate 2001;79;228-235.
60. Assandri R, Egger M, Gassmann M et al. Erythropoietin modulates intracellular calcium in a human neuroblastoma cell line. J Physiol 1999;516:343-352.
61. Juul SE, Anderson DK, Li Y et al. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 1998;43:40-49.
62. Marti HH, Wenger RH, Rivas LA et al. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 1996;8:666-676.
63. Sadamoto Y, Igase K, Sakanaka M et al. Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun 1998;253:26-32.
64. Silva M, Grillot D, Benito A et al. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 1996;88:1576-1582.
65. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999;79:1431-1568.
66. Duffy KR, Pardridge WM, Rosenfeld RG. Human bloodbrain barrier insulin-like growth factor receptor. Metabolism 1988;37:136-140.
67. Golden PL, Maccagnan TJ, Pardridge WM. Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels. J Clin Invest 1997;99:14-18.
68. Pardridge WM, Eisenberg J, Yang J. Human blood-brain barrier transferrin receptor. Metabolism 1987;36:892-895.
69. O'Shaughnessy J, Vukelja S, Savin M et al. Impact of epoetin alfa on cognitive function, asthenia, and quality of life in women with breast cancer receiving adjuvant or neoadjuvant chemotherapy: analysis of 6-month follow-up data. Breast Cancer Res Treat 2002;76:S138.
70. Christensen D. Old drug, new uses? Science News 2002;162:296.
71. Ehrenreich H, Hasselblatt M, Dembowski C et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495-505.
72. Ward AC, Touw I, Yoshimura A. The JAK/STAT pathway in normal and perturbed hematopoiesis. Blood 2000;95:19-29.